Clinical Trials Logo

Carcinoma, Ductal clinical trials

View clinical trials related to Carcinoma, Ductal.

Filter by:

NCT ID: NCT03703492 Not yet recruiting - Breast Cancer Clinical Trials

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

Start date: October 31, 2018
Phase: Phase 2
Study type: Interventional

This prospective, one-arm study which will enroll patients with biopsy-proven DCIS scheduled for diagnostic breast MRI for preoperative staging/extent of disease evaluation as part of standard of care. Eligible patients will be consented for participation in the research study which includes a directed breast PET/MRI with 18F-FES. 18F-FES uptake of the known malignancy will be measured on the PET/MRI examination using standardized uptake values (SUV) and tumor-to-normal tissue ratios.

NCT ID: NCT03684811 Not yet recruiting - Clinical trials for Cohort 1a and 1b: Glioma

A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Start date: October 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas. The study is divided into two parts: single agent FT-2102 followed by combination therapy. Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dose confirmation followed by a Phase 2 investigation of clinical activity in up to 4 cohorts. During the dose confirmation, additional doses or altered dose schedules may be explored. Part 2: An open-label study of FT-2102 in combination with other anti-cancer agents. Patients will be enrolled across 4 different disease cohorts, examining the effect of FT-2102 + azacitidine (glioma and chondrosarcoma), FT-2102+nivolumab (hepatobiliary tumors) and FT-2102+gemcitabine/cisplatin (intrahepatic cholangiocarcinoma). There will be a safety lead-in followed by a Phase 2 evaluation in up to four cohorts of patients.

NCT ID: NCT03669952 Completed - Clinical trials for Outcome of Breast Cancer

Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer

Start date: January 1, 2010
Study type: Observational [Patient Registry]

A prospective observational longitudinal study of 464 patients was performed between 2010 and 2015. Patients with invasive ductal carcinoma (IDC) and ductal carcinoma in situ associated to invasive ductal carcinoma (DCIS +IDC) were included and analyzed.

NCT ID: NCT03614364 Not yet recruiting - Clinical trials for Salivary Duct Carcinoma

Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma

Start date: August 2018
Phase: Phase 2
Study type: Interventional

1. Study outline This is a multicenter, single-arm, phase II trial to evaluate the efficacy and safety of nanoxel plus herzuma combination chemotherapy in patients with metastatic salivary ductal cancer. Approximately 41 patients will be enrolled. Treatment will be continued until disease progression or unacceptable toxicities. Response evaluation will be performed every 2 cycles. 2. Dosing & Treatment schedule D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks (In case of discontinuation of nanoxel without progression, single agent herzuma can be administered until progression)

NCT ID: NCT03543397 Recruiting - Ductal Carcinomas Clinical Trials

MRI in Ductal Carcinoma in Situ (DCIS)

Start date: February 26, 2018
Study type: Observational

Compare the estimate of the lesional size in MRI to that in mammography, taking as a reference the definitive anatomo-pathological size

NCT ID: NCT03523299 Enrolling by invitation - Clinical trials for Invasive Ductal Carcinoma, Breast

Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer

Start date: May 22, 2018
Phase: N/A
Study type: Interventional

This study will investigate the safety, feasibility, and immune response associated with cryoablation of early invasive breast cancer prior to lumpectomy. Based on mouse models, the investigators believe that cryoablation will initiate a stronger immune response relative to the control group. Consenting patients will be randomized to one of two arms: standard of care (control) or cryoablation (intervention). Participants will undergo a blood draw at the time of consent. Those in the control arm will continue with their standard of care lumpectomy. The intervention arm will receive cryoablation 2 weeks before their scheduled lumpectomy and undergo a second blood draw before the lumpectomy.

NCT ID: NCT03507998 Recruiting - Clinical trials for Hepatocellular Carcinoma

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Start date: June 17, 2017
Phase: Phase 1
Study type: Interventional

This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.

NCT ID: NCT03455270 Recruiting - Breast Cancer Clinical Trials

G1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast Cancer

Start date: May 9, 2018
Phase: Phase 1
Study type: Interventional

This is a study to investigate the potential clinical benefit of G1T48 as an oral selective estrogen receptor degrader (SERD) in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. The study is an open-label design, consisting of 2 parts: dose-finding portion (Part 1), and expansion portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 96 patients will be enrolled in the study.

NCT ID: NCT03437915 Not yet recruiting - Breast Cancer Clinical Trials


Start date: May 2018
Phase: N/A
Study type: Interventional

Partial breast irradiation is typically performed after surgical removal of the tumor. Partial breast irradiation allows for focused radiation to the area from which the cancer was removed, sparing breast tissue from the potential bad effects of radiation compared to radiating the whole breast, which was the standard of care for many years. This study is evaluating the use of partial breast irradiation with NIBB performed before surgery instead of after surgery.This should allow researchers to target the cancer even more accurately and result in less normal breast tissue receiving radiation which may cause less side effects and/or a better cosmetic outcome. In this study partial breast treatment will be given with NIBB in 5 treatments over about 1 week. Surgical removal of the tumor will then be performed between 4-12 weeks following radiation treatment. Researchers believe that participant's risk of complications from surgery will not be higher after getting these radiation treatments than it would have been if participants had surgery first, but that is one of the things researchers are studying.

NCT ID: NCT03430765 Completed - Clinical trials for Breast Cancer Female

Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy

Start date: June 21, 2015
Phase: N/A
Study type: Interventional

The proposed study will be a pilot randomized controlled trial comparing treatment as usual (TAU) to treatment as usual plus a brief Acceptance and Commitment Therapy (ACT) intervention (TAU + ACT) with mastectomy and lumpectomy patients identified as at-risk for developing persistent post-operative pain. The ACT intervention is a single individual therapy session scheduled two weeks following surgery. Potential participants will be recruited from the University of Iowa Breast Cancer Clinic. A sample size of n = 30 for each arm will be recruited. An attrition rate of 20% is anticipated so the total N to be recruited for the study is 72 participants. Study measures will consist of self-report questionnaires and medical record data. Data will be collected prior to surgery, one-week after surgery, and 3 months after surgery.